CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Insilico Medicine Cayman TopCo is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Insilico Medicine Cayman TopCo
Shek Kok
New Territories, 00000  Hong Kong Ticker: 36963696
Business Summary
InSilico Medicine Cayman TopCo is a company principally engaged in the research and development of artificial intelligence in pharmaceuticals. The Company is engaged in the research and development of drug discovery engines. In addition, the Company is engaged in the copabdrug discovery and development of disease target identification, generation of novel molecules data, and predicting clinical trial outcomes.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024-----

Industries
SIC Code Description
7372 Prepackaged software
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman, Chief Executive Officer, Founder and Chief Business Officer AleksandrsZavoronkovs 46 6/1/2023 1/29/2019
President AleksandrAliper 36 11/1/2018 2/1/2014
Co-Chief Executive Officer, Chief Scientific Officer, Executive Director FengRen 50 6/1/2023 2/1/2021
7 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 557,418,500 (As of 12/30/2025)
Stock Exchange: HKG


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, January 8, 2026